Please note: Any medical or genetic information present in this entry is not intended as a diagnosis of your problem, but rather is provided as a helpful guide for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. Information is not necessarily complete. Please see your doctor for diagnosis and treatment.

Please note: DNAtraffic database is the project under construction and information on this page is not finished yet.

Delavirdine


ACCESSION NB: DB00705 (APRD00149)


TYPE: small molecule


GROUP: approved


DESCRIPTION:
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. [PubChem]

CATEGORIES:
Anti-HIV Agents Nonnucleoside Reverse Transcriptase Inhibitors Reverse Transcriptase Inhibitors

ABSORPTION: Rapidly absorbed

INDICATION:
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted

PHARMACODYNAMICS:
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine.

MECHANISM OF ACTION:
Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.

PROTEIN BINDING:
98%

METABOLISM:
Hepatic Enzyme Metabolite Reaction Km Vmax Cytochrome P450 3A4 N-desalkyl delavirdine N-desalkylation 5.4 0.44

TOXICITY:
Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.

AFECTED ORGANISMS:
Human Immunodeficiency Virus